Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9852W HIGH $1.75
Volume
1.09 M
Value Traded
3.54 M
Short % Float
9.38%
-12.1%Week
-7.38%1 Month
+12.2%3 Month
+17.95%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.03 B
EPS (TTM)
-0.10
P/E Ratio
-
Ent. Value
1.17 B
Total Shares
746.33 M
Float Shares
383.71 M
Insiders
48.59%
Institutions
28.86%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
OPK Catalyst Timeline
Dated clinical, regulatory and corporate events for Opko Health Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Opko Health Inc.
242Total events
12Upcoming
65Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
OPKO Health to participate in Wells Fargo 21st Annual Healthcare Conference fireside chat
●Debt Royalty FinancingmazdutideCorporate
Issuance of $125 million senior secured notes secured by mazdutide royalty interests
●Enrollment UpdateMDX2001Trial
MDX2001 Phase 1 enrollment proceeding as planned
solid tumors expressing Trop2 and c-Metsource ↗
●Enrollment CompleteMDX2301Trial
MDX2301 Phase 1 enrollment completion expected
COVID-19 preventionsource ↗
◆Poster PresentationOPK8801001Presentation
Preclinical data for OPK8801001 presented at ENDO 2026
acromegalysource ↗
●Oral PresentationOPK8801001Presentation
OPKO Biologics presented preclinical data on OPK8801001 at ENDO 2026
acromegalysource ↗
●Oral PresentationEB612Presentation
Entera Bio presented preclinical data on EB612 at ENDO 2026
hypoparathyroidismsource ↗
●Oral PresentationEB618Presentation
Entera Bio presented preclinical data on EB618 at ENDO 2026
obesity and metabolic disorderssource ↗
●Oral PresentationPresentation
ModeX presented data on multispecific antibody targeted in vivo CAR T cell programs at ASGCT Annual Meeting
●Trial InitiationMDX2301Trial
Initiated MDX2301 Phase 1 clinical trial for prevention of COVID-19
COVID-19 preventionsource ↗
●Trial InitiationMDX2003Trial
Initiated MDX2003 Phase 1 clinical trial in relapsed or refractory B-cell lymphoma
relapsed or refractory B-cell lymphomasource ↗
●Trial InitiationOPK-88006Trial
Initiated Phase 1/2a clinical study of OPK-88006 in healthy and presumed MASH participants
MASHsource ↗
▲Partnership / LicenseRayaldeeApprovedCorporate
Expanded Nicoya Agreement to Support RAYALDEE Commercialization in Greater China
▲Partnership / LicenseCorporate
OPKO and Entera expand partnership to develop oral LA-PTH for hypoparathyroidism
hypoparathyroidismsource ↗
◆Trial InitiationMDX2001Trial
Phase 1b studies for MDX2001 expected to begin in early 2026
advanced solid tumorssource ↗
◆Poster PresentationMDX2004Presentation
Poster presentations at SITC 2025 for MDX2004 preclinical data
advanced cancerssource ↗
●Poster PresentationMDX2003Presentation
MDX2003 abstract presented at ASH 2025
B cell malignanciessource ↗
●Poster PresentationMDX2004Presentation
MDX2004 abstract presented at SITC 2025
advanced cancerssource ↗
▲Partnership / LicenseCorporate
Research collaboration with Regeneron to develop multispecific antibodies
▲First Patient DosedMDX2004Trial
First patient dosed in MDX2004 Phase 1/2a study
advanced cancerssource ↗
●Oral PresentationMDX2001Presentation
Abstract presented at ESMO 2025 for MDX-2001
advanced solid tumorssource ↗
▲Partnership / LicenseCorporate
Research collaboration with Regeneron to develop multispecific antibodies
▲IND ClearanceMDX2003IND
MDX2003 approved for Phase 1 studies in Australia
leukemia and lymphomasource ↗
●Poster PresentationMDX2001Presentation
MDX2001 abstract presented at ESMO 2025
advanced solid tumorssource ↗
▲Dose Finding UpdateMDX2001Trial
MDX2001 advanced to fifth dose level in Phase 1
advanced solid tumorssource ↗
▲AcquiredCorporate
Labcorp completes acquisition of select assets of BioReference Health's oncology and related clinical testing businesses
●Oral PresentationPresentation
Abstract presented at ESPEN 2025 for oral GLP-2 tablet
short bowel syndromesource ↗
◆AbstractPresentation
Abstract on oral GLP-2 tablet selected for ESPEN Congress 2025
short bowel syndromesource ↗
▲sNDA SubmissionRegulatory Filing
FDA approved supplemental application for 4Kscore Test without DRE
prostate cancersource ↗
●Oral PresentationOPK-88006Presentation
Abstract presented at ENDO 2025 for oral dual GLP-1/glucagon tablet
obesity and metabolic disorderssource ↗
▲FDA ApprovalFDA Decision
FDA approved supplemental application for 4Kscore Test without DRE information
prostate cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How OPK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | MDX2301 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C52 / 100
Pipeline Score
$1.2B
Pipeline Value
$1.4B
Commercial Value
Undervalued
Valuation Signal
6
Drugs Scored
3.9x
rNPV / MCap
Top 15%
Micro Cap(rank 100 of 660)
Percentile Rank
Opko Health Inc. carries a moderate pipeline score (52/100), with $3.0B risk-adjusted pipeline value, led by OPK-88003 in Type 2 Diabetes Mellitus (Phase 2), across $122B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Jun 2026; product lines from the latest annual filing) Revenue $587.9M x 2.4 = $1.4B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Rayaldee | $30M | $29M | +2.8% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OPK-88003 Small moleculeCompletedNCT03406377 | Type 2 Diabetes Mellitus | Phase 2 | COMPLETED | 113 | Jun 27, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every OPK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OPK-88006 | metabolic dysfunction-associated steatohepatitis (MASH) | 2025-07-31 | the therapeutic benefits of OPK-88006 on quantitative biological hallmarks of MASH were superior to semaglutide and survodutideRead More | OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMIRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PAGANELLI JOHN ADirector | Buy | 10,000 394,340 held | $1.14 | 03/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OPK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in OPK for Q2 2026. | ||||
OPK Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OPK ranks across every disease it competes in
Competitive Position is a premium feature
See how OPK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOPK News
-OPK
Sep 8, 2026OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
OPKO Health, Inc. will participate in the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. Key executives, including Dr. Elias A. Zerhouni and Adam Logal, will engage in a fireside chat. The event highlights OPKO's focus on serious diseases and its strategic positioning in the healthcare market.
Read more →-OPK
Aug 13, 2026OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
OPKO Health has expanded its financing relationship with HealthCare Royalty by issuing $125 million in senior secured notes. The notes are backed by royalty interests from OPKO's mazdutide agreement with Eli Lilly, maturing in 2044. This move allows OPKO to access non-dilutive capital while retaining long-term benefits from the mazdutide franchise, which is being commercialized in China.
Read more →-OPK
Jul 27, 2026▲ +33.1%on this news
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
OPKO Health, Inc. reported its second quarter 2026 business highlights and financial results, showcasing improved revenues and the initiation of several Phase 1 clinical trials. The company is advancing its innovative therapies, including a bispecific antibody for COVID-19 and a tetraspecific T-cell engager for B-cell lymphoma. Despite a significant reduction in operating losses, revenue from services declined due to asset sales. The company also expanded its collaboration with Entera Bio, enhancing its pipeline potential.
Read more →-OPK
Jul 23, 2026OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
OPKO Health, Inc. announced it will report its second-quarter 2026 financial results on July 27, 2026. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide financial guidance. Participants can pre-register for the call to gain immediate access.
Read more →-OPK
Jun 15, 2026Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
OPKO Biologics presented promising preclinical data for OPK8801001 at ENDO 2026, indicating its potential as a long-acting treatment for acromegaly. The data demonstrated significant suppression of IGF-1 levels, suggesting a weekly dosing alternative to current daily therapies. The findings reinforce OPKO's commitment to developing innovative treatment options for patients with endocrine disorders.
Read more →-OPK
May 12, 2026OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
ModeX Therapeutics, a subsidiary of OPKO Health, will present preclinical data on its MDX3001 candidate at the ASGCT 2026 Annual Meeting. The data showcases in vivo CAR-T cell generation and systemic B-cell depletion in animal models. The innovative CD3xCD28 antibody-conjugated LNP/mRNA platform demonstrates significant potential for treating various diseases without the need for pre-conditioning chemotherapy.
Read more →-OPK
Apr 30, 2026OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
OPKO Health has expanded its agreement with Nicoya Therapeutics, granting OPKO a 15% equity stake in Nicoya. This amendment supports the commercialization of RAYALDEE in Greater China, where it is already approved in Macau. The companies anticipate regulatory approvals in China by 2027, aiming to address the needs of patients with chronic kidney disease.
Read more →-OPK
Apr 30, 2026BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
BioReference Health LLC has launched BioReference Direct, a digital platform that allows consumers to access laboratory testing directly. This initiative aims to enhance patient-driven healthcare by providing a seamless online experience for selecting tests. The platform includes various health panels and an at-home STI test in collaboration with Abbott, promoting early detection and proactive health management.
Read more →-OPK
Apr 29, 2026▼ -8.3%on this newsshared move
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
OPKO Health, Inc. reported its business highlights and financial results for the first quarter of 2026. The company reaffirmed its financial guidance for the year and scheduled a conference call to discuss these results. However, the report included cautionary forward-looking statements regarding product development and regulatory challenges.
Read more →-OPK
Apr 22, 2026OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
ModeX Therapeutics, a subsidiary of OPKO Health, has initiated a Phase 1 clinical trial for MDX2003, a tetraspecific T-cell engager targeting B-cell lymphomas. This study aims to evaluate the safety and efficacy of MDX2003 in patients with relapsed or refractory B-cell lymphoma. The trial is designed to assess pharmacokinetics and immune activity, building on promising preclinical results.
Read more →-OPK
Feb 27, 2026OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
OPKO Health, Inc. will participate in the Jefferies Biotech on the Beach Summit on March 10-11, 2026, at 1 Hotel South Beach in Miami. The company plans to hold one-on-one meetings with registered investors on March 11. This engagement aims to strengthen investor relations and showcase OPKO's biopharmaceutical and diagnostics expertise.
Read more →-OPK
Feb 26, 2026OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. has reported its fourth-quarter business highlights and financial results for 2025, showcasing a collaboration with Regeneron Pharmaceuticals estimated to exceed $1 billion in potential value. The company announced advancements in clinical trials for novel cancer treatments MDX2003 and MDX2004, while also presenting an increase in revenue from product sales. However, total consolidated revenues have decreased, attributed to prior asset sales, along with a rise in operating losses when compared to the same quarter last year.
Read more →-OPK
Feb 12, 2026OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
OPKO Health, Inc. plans to report its financial results for Q4 2025 on February 26, 2026. The announcement includes a conference call where senior management will discuss the results and provide financial guidance. Participants can pre-register for easier access to the call, which will also be available via webcast.
Read more →-OPK
Feb 4, 2026OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
OPKO Health and Entera Bio have expanded their partnership to develop a first-in-class oral long-acting PTH tablet for hypoparathyroidism. The companies plan to file an IND application with the FDA in late 2026, following promising preclinical data. This collaboration aims to provide a more convenient treatment option for patients, moving away from daily injections.
Read more →-OPK
Oct 29, 2025OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. reported their third quarter 2025 business highlights and financial results, including significant developments such as a partnership with Regeneron Pharmaceuticals to develop multispecific antibodies. The sale of BioReference Health clinical assets for $225 million is expected to enhance OPKO's financial stability. While total revenues declined compared to the previous year, the company made strides in advancing its oncology and vaccine programs, showcasing its commitment to innovation in the health sector.
Read more →-OPK
Sep 15, 2025Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Labcorp has completed the acquisition of select assets from BioReference Health, a subsidiary of OPKO Health, enhancing its oncology clinical testing services. The deal, valued at up to $225 million, aims to provide expanded access to quality laboratory services across the U.S. Through this acquisition, Labcorp is committed to improving cancer care. OPKO Health plans to focus on its core clinical testing operations and intends to use part of the proceeds for share repurchase.
Read more →-OPK
Jul 31, 2025OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. reported its second-quarter financial results and business highlights for 2025. The company noted advancements in its vaccine trials in collaboration with Merck and the development of its novel drug OPK-88006, which demonstrated promising data for treating metabolic diseases. The FDA approved the 4KScore Test, enhancing its use in cancer assessments. However, OPKO experienced a decline in revenue and an increased net loss compared to the previous year, primarily due to significant non-recurring expenses.
Read more →-OPK
Mar 8, 2023▲ +6.6%on this news
Document OPKO Health's ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate MDX-2201 leverages ModeX's innovative biologics pla
OPKO Health's ModeX Therapeutics has entered an exclusive worldwide license and collaboration agreement with Merck to develop MDX-2201, a nanoparticle vaccine targeting Epstein-Barr virus (EBV). This collaboration is marked by an upfront payment of $50 million, with potential milestone payments up to $872.5 million. MDX-2201 employs ModeX's innovative multitargeting approach to target multiple EBV proteins, aiming to improve protective immunity. The partnership leverages both companies' strengths in vaccine development to tackle a critical health issue associated with EBV infections.
Read more →-OPK
Feb 23, 2023▲ +5.7%on this news
Document OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (
OPKO Health, Inc. released its fourth quarter 2022 financial results, revealing a revenue of $185.4 million compared to $401.3 million in the previous year. The company saw an increase in pharmaceutical revenue driven by products like RAYALDEE, despite a notable decline in diagnostics revenue due to reduced COVID-19 testing. The firm reported an operating loss of $55.3 million, reflecting higher costs and expenses, while a $2.5 million revenue was recognized from Nicoya. OPKO's management will provide an update and discuss these results during a conference call today.
Read more →-OPK
Nov 8, 2022Document OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (
OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (November 8, 2022) - OPKO Health, Inc. (NASDAQ OPK) reports business highlights and financial results for the three months ended Septemb
Read more →About Opko Health Inc.
Headquarters4400 BISCAYNE BLVD., MIAMI, FL, 33137
BIOPHARMAWATCH ELITE PLUS
Trade the next OPK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime